We recently published a list of 35 Non-Tech AI Opportunities Amid DeepSeek Selloff. In this article, we are going to take a ...

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech ...

SAN FRANCISCO—Nvidia will partner with Illumina to apply genomics and AI technologies to analyze and interpret multi-omic data in drug discovery, clinical research, and human health, the ...

Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of the National Institutes of Health’s All of Us million-person program ...

SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology ...

NEW YORK (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals, Illumina and 17 U.S. health systems will take a $320 million stake in the company as part ...

The tech company has partnered with clinical research services company IQVIA, genomics specialist Illumina, and Mayo Clinic. Along with a collaboration with research organisation Arc Institute, the ...

The 25 largest subsidiaries of internationally-owned companies are also listed by turnover in the county, with Granta Park-based sequencing giant Illumina Cambridge first, followed by semiconductor ...

Illumina has begun rolling out a series of updates to its top-of-the-line DNA sequencer models, with the goal of making the high-throughput machines more attractive to smaller laboratories. For it ...

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...